The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with ...
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...
Kura Oncology (KURA) and Kyowa Kirin provided encouraging clinical data from KOMET-007, a Phase 1 dose-escalation trial of ziftomenib, a highly ...
Bionomics (BNOX) announced that the results from its Phase 2 ATTUNE study have been published in the NEJM Evidence. The data were also ...
The FDA has accepted the New Drug Application for donidalorsen, an investigational RNA-targeted medicine for preventing HAE attacks.
Palantir Technologies Inc. today announced an expansion of its contract with the U.S. Special Operations Command (USSOCOM) to deliver technology solutions in support of enterprise capabilities. The ...
The progression-free survival (PFS) rate at 5 years improved from 40.8% with active monitoring and no disease-specific ...
Cogent Biosciences, Inc. (NASDAQ:COGT) revealed updated clinical results from the Open Label Extension (OLE) portion of the ...
AFM28, a bispecific, tetravalent innate cell engager (ICE ®) targeting CD123 and CD16A, achieved a 40% composite complete ...
The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for paltusotine for the treatment and long-term maintenance of acromegaly in adults.
A subgroup analysis showed that epcoritamab is effective regardless of CAR T–exposure in patients with R/R LBCL.
Implementing an individualized starting dose (ISD) of niraparib (Zejula; GSK) reduced severe hematologic adverse event (AE) ...